Abstract
(68)Ga-DOTATATE positron emission tomography (PET) is a molecular imaging technology which has shown superiority over (111)In-octreotide scanning for the detection and staging of neuroendocrine tumors. We report three patients with pancreatic masses that were ultimately diagnosed as clear cell renal cell carcinoma (ccRCC) metastases on histopathology. During their initial diagnostic assessment, the three patients underwent both (18)F-fluorodeoxyglucose ((18)F-FDG) and (68)Ga-DOTATATE PET. While all three patients' lesions showed variable (18)F-FDG avidity, uptake on (68)Ga-DOTATATE PET was comparatively intense. The small case series illustrates the need to consider ccRCC in the differential diagnosis of (68)Ga-DOTATATE avid lesions.